<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03277339</url>
  </required_header>
  <id_info>
    <org_study_id>InsulaTOP</org_study_id>
    <nct_id>NCT03277339</nct_id>
  </id_info>
  <brief_title>Psycho-biological Substrates of Therapeutic Benefit of Thermal Cure on Generalized Anxiety Disorders</brief_title>
  <acronym>Insula-TOP</acronym>
  <official_title>Psycho-biological Substrates of Therapeutic Benefit of Thermal Cure on Generalized Anxiety Disorders (Insula-TOP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Henri Laborit</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Association Francaise pour la Recherche Thermale</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Les thermes de Saujon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre National de la Recherche Scientifique (CeRCA, umr 7295), France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Henri Laborit</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter study comparing paroxetine (n=30) versus thermal cure (n=30) in patients with a
      diagnosis of Generalised Anxiety Disorders
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicenter study comparing paroxetine (n=30) versus thermal cure (n=30) in patients with a
      diagnosis of Generalised Anxiety Disorders

      Main objective is to quantify the therapeutic benefit of a thermal cure on generalized
      anxiety disorders and to understand the psycho-biological substrates of this improvement.

      Secondary objectives:

        -  A decrease of Insula activity at rest during the answers to aversive pictures and during
           the task of subjective measurement of heartbeat.

        -  A decrease of sensibility to emotional interference by subliminal presentation of
           emotional words thanks to a lexical task and a color recognition task associated to
           simultaneous measurement of physiological indicator of emotional activity ( dermal
           resistance)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 19, 2017</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease Insula activity during a resting state task</measure>
    <time_frame>The evaluation of primary end point is performed between day 1 and day 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of HAM-A score between day 1 and day 24.</measure>
    <time_frame>The evaluation of primary end point is performed between day 1 and day 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensibility non conscientious to emotional interference in lexical task and in color identification task</measure>
    <time_frame>D= Day D1/D24/D56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modulation of electrodermal response during presentation of predictive stimuli on aversive images and its links to the subjective view of emotional state</measure>
    <time_frame>D= Day D24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modulation of electrodermal response during presentation of predictive stimuli on aversive images and insula activation</measure>
    <time_frame>D= Day D24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lost of significant correlation (Day 24) between HAM-A score, introspective acuity and insula hyperactivation</measure>
    <time_frame>D= Day D24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution (Day 1 and Day 24) of the correlation between HAM-A global score and 1- the measure of heartbeat 2- emotional reactivity during aversive images task.</measure>
    <time_frame>D= Day D1/D24.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference (Day 1 and Day 24) of correlations between the symptoms severity and the activation of insula cortex during 1-aversive images task, 2-heartbeat measure task.</measure>
    <time_frame>D= Day D1/D24.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of efficacy of the thermal cure Day 56 using HAM-A score</measure>
    <time_frame>D= Day D56</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Generalized Anxious Disorders</condition>
  <arm_group>
    <arm_group_label>Paroxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paroxetine (Deroxat®) Posology : 20 mg per day for 3 weeks. After 2 weeks of treatments, if indicated, physicians will prescribe until 50 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thermal cure</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This study is controlled with a comparator which is the Thermal cure. Thermal cure is realized for 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paroxetine</intervention_name>
    <description>Deroxat® (20 mg/day) 3 week; can be increase on week 2 until 50 mg.</description>
    <arm_group_label>Paroxetine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Thermal cure</intervention_name>
    <description>Thermal cure is realized for 3 weeks</description>
    <arm_group_label>Thermal cure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnostic of generalized anxiety disorder according to the Diagnostic and Statistical
             Manual of Mental Disorders (DSM IV)

          -  No treatment by antidepressant for at least 2 months

          -  No treatment by anxiolytic/neuroleptic/bete blockers/antipsychotic for at least 3
             weeks

          -  Global score of Hamilton Anxiety Scale (HAM-A) is greater or equal to 20

          -  Score of HAM-A symptoms greater or equal to 8

          -  Score of Hamilton Depressive Scale (HAM-D) lower or equal to 7

          -  Age: Participants will be males and females, 18-75 years of age included.

          -  For women, no ongoing pregnancy/ negative pregnancy test

          -  No wounds

          -  Affiliation to a social security system (recipient or assignee)

          -  Signed written inform consent form

        Exclusion Criteria:

          -  Treatment by antidepressant for at least 2 months or a treatment by anxiolytic,
             neuroleptic for at least 3 weeks

          -  Psychotropic treatment (antidepressant, anxiolytic and neuroleptic) between the
             preinclusion and inclusion

          -  Psychotherapy during the 3 months prior to the inclusion

          -  Thermal cure during the 6 months prior to the inclusion

          -  Treatment by paroxetine for at least 1 month with dose equal or superior to 20 mg per
             day during the 12 months prior to the inclusion

          -  Contraindication to paroxetine

          -  Enhanced protection (minors, pregnancies women, nursing women,people deprived of
             liberty by administrative or judicial decision, ...)

          -  Blood donation during the 3 months prior to the inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JAAFARI Nematollah, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Henri Laborit</affiliation>
  </overall_official>
  <overall_official>
    <last_name>INGRAND Pierre, MD-PhD-PU-PH</last_name>
    <role>Study Chair</role>
    <affiliation>Centre d'investigation clinique INSERM CIC P802</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>JAAFARI Nematollah, MD-PhD</last_name>
    <phone>05 16 52 61 18</phone>
    <email>nemat.jaafari@ch-poitiers.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>LANGBOUR Nicolas, PhD</last_name>
    <phone>05 16 52 61 18</phone>
    <email>Nicolas.langbour@ch-poitiers.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Henri Laborit</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nematollah Jaafari, PU-PH</last_name>
      <phone>+33 5 16 52 61 18</phone>
      <email>nemat.jaafari@ch-poitiers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Les thermes de Saujon</name>
      <address>
        <city>Saujon</city>
        <zip>17600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DUBOIS Olivier, MD</last_name>
      <email>thermes.odubois@wanadoo.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Jaafari N, Rachid F, Rotge JY, Polosan M, El-Hage W, Belin D, Vibert N, Pelissolo A. Safety and efficacy of repetitive transcranial magnetic stimulation in the treatment of obsessive-compulsive disorder: a review. World J Biol Psychiatry. 2012 Mar;13(3):164-77. doi: 10.3109/15622975.2011.575177. Epub 2011 May 30. Review.</citation>
    <PMID>21623668</PMID>
  </reference>
  <reference>
    <citation>Jaafari N, Baup N, Bourdel MC, Olié JP, Rotge JY, Wassouf I, Sharov I, Millet B, Krebs MO. Neurological soft signs in OCD patients with early age at onset, versus patients with schizophrenia and healthy subjects. J Neuropsychiatry Clin Neurosci. 2011 Fall;23(4):409-16. doi: 10.1176/jnp.23.4.jnp409.</citation>
    <PMID>22231312</PMID>
  </reference>
  <reference>
    <citation>Jaafari N, Aouizerate B, Tignol J, El-Hage W, Wassouf I, Guehl D, Bioulac B, Daniel ML, Lacoste J, Gil R, Burbaud P, Rotge JY; Insight Study Group. The relationship between insight and uncertainty in obsessive-compulsive disorder. Psychopathology. 2011;44(4):272-6. doi: 10.1159/000323607. Epub 2011 May 6. Erratum in: Psychopathology. 2011;44(5):319.</citation>
    <PMID>21546788</PMID>
  </reference>
  <reference>
    <citation>Girard SL, Gauthier J, Noreau A, Xiong L, Zhou S, Jouan L, Dionne-Laporte A, Spiegelman D, Henrion E, Diallo O, Thibodeau P, Bachand I, Bao JY, Tong AH, Lin CH, Millet B, Jaafari N, Joober R, Dion PA, Lok S, Krebs MO, Rouleau GA. Increased exonic de novo mutation rate in individuals with schizophrenia. Nat Genet. 2011 Jul 10;43(9):860-3. doi: 10.1038/ng.886.</citation>
    <PMID>21743468</PMID>
  </reference>
  <reference>
    <citation>Dubois O, Salamon R, Germain C, Poirier MF, Vaugeois C, Banwarth B, Mouaffak F, Galinowski A, Olié JP. Balneotherapy versus paroxetine in the treatment of generalized anxiety disorder. Complement Ther Med. 2010 Feb;18(1):1-7. doi: 10.1016/j.ctim.2009.11.003. Epub 2010 Jan 6.</citation>
    <PMID>20178872</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2017</study_first_submitted>
  <study_first_submitted_qc>September 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2017</study_first_posted>
  <last_update_submitted>September 13, 2017</last_update_submitted>
  <last_update_submitted_qc>September 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Generalized anxious disorders</keyword>
  <keyword>Thermal cure</keyword>
  <keyword>paroxetine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paroxetine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

